FBI

Products/ssdssgfbb3.jpg
In stock

SupplySide Global F&B Education: Regulatory Bundle

Tariffs and turbulence: Overcoming food and beverage supply chain challenges

It’s unlikely we’ll be able to move the entire ingredient procurement process solely within the United States — even over the next decade — so where do we go from here? Join us for what is sure to be an enlightening session on navigating issues such as ingredient shortages, transparency and the political landscape. You’ll come out of this session with some fresh ideas on how to diversify your supply chain within the context of a trade war.

Not on my watch: Why product safety can’t wait until launch 

Food and supplement safety isn’t just a regulatory box to check — it’s a humane responsibility. In a landscape full of bold claims, new ingredients and faster-than-ever launch timelines, food safety must be more than an afterthought. This session brings together leading food and supplement safety experts to unpack where things can go wrong; how to build safety into every phase of development; and what’s coming next in shelf life, packaging and regulatory oversight.

Unfiltered: Politics, policy and profit in the future of supplements, foods and beverages

It’s not business as usual. In this session, we’ll dig into what’s really driving the supplement and food and beverage industry right now—from shifting sales trends and tariff impacts to the growing influence of political figures like Robert F. Kennedy Jr. We’ll kick things off with fresh data, then move into a candid panel discussion exploring how political movements, public skepticism and anti-establishment messaging are reshaping consumer trust and product innovation. Whether you’re energized by these shifts or approaching them with caution, this session will help you make sense of what’s happening — and what it means for the future of supplements.

Too supplement to be pharma, too pharma to be food

Supplements, pharmaceuticals and functional foods are in a full-blown situationship — and it’s getting messy. As brands blur lines across categories and take space in wellness, performance and even disease-adjacent benefits, the question of “who gets to play with what ingredient” is heating up. Drug preclusion rules are being tested, pharma collabs are popping up and regulatory gray zones are getting grayer. This session will spotlight real-world examples — ingredients like NAC (N-acetyl-cysteine), NMN (nicotinamide mononucleotide) and CBD (cannabidiol) — where regulatory red flags, pharma filings or shifting FDA interpretations threw a wrench into innovation. We'll also explore what could happen when supplement and pharma companies try to team up, and what’s at stake when functional ingredients push against regulatory lines.